Skip to main content
Oncodesign Precision Medicine S.A logo

Oncodesign Precision Medicine S.A — Investor Relations & Filings

Ticker · ALOPM ISIN · FR001400CM63 LEI · 969500ZDX1IY47LDL876 Euronext Access Plus Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2024-04-18 Regulatory Filings
Country FR France
Listing Euronext Access Plus ALOPM

About Oncodesign Precision Medicine S.A

https://www.oncodesign.com/

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the brokerage firm Degroof Petercam has initiated research coverage on Oncodesign Precision Medicine (OPM) shares, including a target price range. This announcement is not a formal regulatory filing like a 10-K or IR, nor is it a transcript, dividend notice, or management change. It is an announcement related to investor relations and market coverage. Since it is a specific announcement about investor coverage/research initiation, it fits best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially 'Investor Presentation' (IP) if it were the presentation itself, but here it is an announcement *about* research. Given the options, and that it's a press release detailing external analyst coverage, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although it is closely related to investor communication. However, since it is a press release announcing external research, and not a formal report or a standard IR/ER/DIV/MANG announcement, RNS serves as the best fit among the provided codes for a general corporate news release that doesn't fit elsewhere.
2024-04-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the investment bank Degroof Petercam has initiated research coverage on Oncodesign Precision Medicine (OPM), including issuing a first financial analysis and a price target range. This announcement is not a formal regulatory filing like a 10-K or an earnings release (ER). It is an announcement related to investor relations, specifically concerning external analysis and valuation. Since it is a press release announcing an analyst report/coverage initiation, it fits best under the general category for regulatory/corporate announcements that don't fit specific financial reporting types. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate announcement of this nature, although 'Investor Presentation' (IP) or 'Earnings Release' (ER) are related to investor communication, this is specifically about *external analyst coverage* being initiated, which is often disseminated via a general press release. However, upon reviewing the definitions, none perfectly capture 'Analyst Coverage Initiation Announcement'. It is a communication aimed at investors about external valuation. Since it is a press release announcing a corporate event/update (analyst coverage), and it is not a formal financial report, the best fit among the provided codes is RNS (Regulatory Filings) as a general announcement category, or potentially LTR if it were related to legal matters, or ER if it were financial results. Given the context of external financial analysis being made public, RNS serves as the best general announcement category fallback.
2024-04-18 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces that Oncodesign Precision Medicine (OPM) has received a public funding award of €5.6 million from the France 2030 plan for its DEMOCRITE program related to the clinical development of OPM-101. This is a specific announcement regarding financing/funding received by the company for a project, which aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it is a direct announcement of receiving funds, it is classified as CAP rather than the general 'Regulatory Filing' (RNS). The document length (10,496 chars) is substantial, indicating it is the primary announcement, not just a brief notice of publication.
2024-04-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that Oncodesign Precision Medicine (OPM) has obtained €5.6 million in public funding for its DEMOCRITE program. It details the funding source (France 2030 plan via bpifrance), the amount, and the purpose (clinical development of OPM-101). This type of announcement, focusing on significant corporate news, funding events, or material non-financial developments, is typically classified as a general regulatory announcement or press release. Since there is no specific category for 'Press Release' or 'Funding Announcement' that perfectly matches, and it is not a formal statutory filing (like 10-K, AR, IR, ER), the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers general regulatory announcements that don't fit elsewhere. It is not an Earnings Release (ER) as it focuses on funding, not financial results, nor is it a Capital/Financing Update (CAP) which usually relates to issuing securities or debt, although this is related to funding, the format is a press release of a grant award.
2024-04-17 English
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "OPM publishes its annual results for 2023 and provides an update on its clinical developments" and contains a detailed, audited Income Statement for the years 2023 and 2022, along with management commentary on financial performance and R&D investment. This strongly indicates it is the company's primary annual financial disclosure. However, the document explicitly states: "The 2023 Financial Report will be available on the company's website on 25 April 2024. The work of the Statutory Auditor is currently being finalized." This means the document provided is likely the press release announcing the results, which typically precedes the formal 10-K filing or the full Annual Report (AR). Since it contains the full audited figures and management discussion, it functions as the core financial reporting document, but the explicit mention of the final report being forthcoming suggests it is an Earnings Release (ER) or a precursor to the full Annual Report (10-K/AR). Given the depth of the financial tables and management discussion, it is more substantial than a typical ER, but the explicit reference to the final report being pending makes it slightly ambiguous. However, the content is clearly the comprehensive annual financial summary. In the context of the provided definitions, a document that publishes the full annual results, including the income statement, aligns best with the scope of an Annual Report (10-K) or a comprehensive Audit Report (AR). Since it is a press release announcing the results, and not the final statutory filing, and it contains the full financial breakdown, it is classified as an Earnings Release (ER) as it is the initial announcement of the annual results, even though it is very detailed. If the document were the final, filed report, it would be 10-K or AR. Since it is the announcement of the results, ER is the most appropriate fit among the choices, as it summarizes the annual performance. FY 2023
2024-03-26 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release announcing the company's 'résultats annuels 2023' (2023 annual results). It contains key financial highlights (revenue, loss, cash position) for the full year 2023, comparative figures for 2022, management commentary, and details on R&D spending. This content strongly aligns with an Earnings Release (ER) or a summary preceding a full Annual Report (10-K). However, the text explicitly states: "Le Rapport Financier 2023 sera disponible sur le site internet de la société, le 25 avril 2024." This indicates that the document provided is the initial announcement of the results, not the comprehensive, audited Annual Report (10-K) itself, nor the formal Audit Report (AR). Furthermore, it contains detailed financial tables and management discussion, making it more substantial than a typical brief Earnings Release (ER). Given the comprehensive nature of the financial review and the announcement of the final audited report's future release date, this functions as the primary financial results announcement. In the context of the provided definitions, 'ER' (Earnings Release) is the best fit for the initial announcement of periodical financial results (key highlights only), even though this one is quite detailed. If the document were the full, final report, it would be 10-K. Since it is the announcement *of* the annual results, ER is appropriate, as it precedes the formal 10-K filing. FY 2023
2024-03-26 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.